Fair Prescription Drug Prices for Americans Act
- Bill Number
- H.R. 3375
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-05-13: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-12-05T22:53:28Z
AI-Generated Summary
Purpose
The "Fair Prescription Drug Prices for Americans Act" (H.R. 3375) aims to lower the cost of certain prescription drugs and biological products in the United States by capping their retail list prices at a level that does not exceed the average retail list price in six other high-income countries: Canada, France, Germany, Italy, Japan, and the United Kingdom. This is intended to make pricing more equitable by referencing international benchmarks.
Key Provisions
- Definitions:
- Biological product: A product licensed under specific sections of the Public Health Service Act, essentially complex medicines derived from living organisms (e.g., vaccines or insulin).
- Drug: A medication approved under the Federal Food, Drug, and Cosmetic Act, covering traditional small-molecule drugs.
- Secretary: Refers to the Secretary of Health and Human Services (HHS), the federal official overseeing health policy implementation.
- Price Cap: The retail list price (the manufacturer's suggested price before discounts) for these drugs and biological products in the U.S. cannot exceed the average retail list price in the specified six countries.
- Calculation of Average Price: HHS must annually compute the average using:
- Data reported by manufacturers.
- Publicly available filings from manufacturers in those countries.
- Enforcement Penalty: Manufacturers violating the price cap face a civil monetary penalty (a fine) calculated as:
- The difference between the U.S. list price and the international average, multiplied by 10.
- This penalty applies per unit sold, making it scalable based on sales volume.
- Data Reporting Requirement: Manufacturers must submit annual list prices to HHS for their products in the U.S. and the six reference countries.
- Implementation: HHS will issue guidance and create regulations to put these rules into effect.
Significant Changes to Existing Law
This bill introduces a new system of international reference pricing, where U.S. drug prices are directly tied to averages from other nations—a concept not currently in federal law. Previously, U.S. drug prices have been unregulated at the federal level in terms of international comparisons, leading to often higher costs compared to other countries. It builds on existing approval processes for drugs and biological products but adds pricing oversight and penalties, shifting from a market-driven approach to one with government-enforced limits.
Potential Impacts
- On Citizens: Could reduce out-of-pocket costs for patients and improve access to expensive medications, potentially benefiting millions who rely on these drugs for chronic conditions.
- On Government Agencies: HHS gains new responsibilities for data collection, price calculations, enforcement, and rulemaking, which may require additional resources and staff. Revenue from penalties could offset some costs but might strain administrative capacities.
- On International Relations: May influence trade dynamics with the reference countries, as U.S. pricing could pressure global manufacturers to adjust strategies. It might encourage similar pricing transparency internationally but could complicate negotiations if foreign governments view it as interfering with their markets.
- Broader Economic Effects: Lower U.S. prices might reduce overall healthcare spending but could affect drug innovation incentives if manufacturers cut research budgets in response.
Main Stakeholders Affected
- Drug and Biological Product Manufacturers: Primary targets, as they must report prices, comply with caps, and risk significant fines for non-compliance.
- Patients and Consumers: Stand to gain from potentially lower prices, especially those with high-deductible insurance or paying out-of-pocket.
- Healthcare Providers and Insurers: Could see indirect benefits through reduced reimbursement costs, though they might face adjustments in supply chains.
- HHS and Federal Government: Responsible for oversight, enforcement, and data management.
- Pharmacies and Retailers: Affected by list price changes, which influence wholesale and retail pricing.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill's penalty structure could face challenges under administrative law if seen as overly punitive or if data collection raises privacy concerns. It may intersect with existing antitrust laws, as price caps could be argued to restrain trade.
- Constitutional: Potential issues with the Commerce Clause (regulating interstate economic activity) or Takings Clause (if penalties are viewed as seizing property without due process), though courts have upheld similar health regulations. No direct free speech or equal protection concerns are evident.
- Political: Addresses widespread public frustration with high U.S. drug prices, potentially appealing across party lines, but could spark debate over government intervention in markets versus consumer protection. If enacted, it might set a precedent for broader price controls in healthcare.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Van Drew, Jefferson [R-NJ-2]
Recent Actions
- 2025-05-13: Referred to the House Committee on Energy and Commerce.
- 2025-05-13: Introduced in House
- 2025-05-13: Introduced in House
Bill Versions
- Fair Prescription Drug Prices for Americans Act — issued 2025-05-13 — PDF (4 pages)